Skip the wait and schedule your appointments online or through MyChart.

COVID Vaccine Now Available for Ages 6 months+ – Learn More

Research & Innovation


Clinical Trials

SLUHN 2015-60

Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AB103 as Compared to Placebo in Patients With Necrotizing Soft Tissue Infections. ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)

Physician & Study Coordinator


John Lukaszczyk, MD

John Lukaszczyk, MD

Study Coordinator

Thomas Parsons, RN CCRP



Synopsis: The purpose of this study is to determine whether AB103 is safe and effective in the treatment of patients with necrotizing soft tissue infections receiving standard of care therapy.


Inclusion Criteria
  • Age: ≥18 years
  • Surgical confirmation of NSTI by attending surgeon (e.g. presence of necrotic tissue, thrombosed vessels in the subcutaneous tissue, lack of bleeding and “dishwater” (cloudy, thin, gray) fluid) due to presumed bacterial infection (necrotizing cellulitis (most commonly group A strep), necrotizing fasciitis, necrotizing myositis and myonecrosis, NSTI of the perineum, bacterial synergistic gangrene, Clostridial gas gangrene) that may be supported by specific signs and symptoms (e.g. tense edema outside area of compromised skin, pain disproportionate to appearance, skin discoloration, ecchymosis, blisters/bullae, necrosis, tense edema, crepitus and/or subcutaneous gas).
    • Patients with NSTI following intra-abdominal operation are eligible if adequate source control of intra-abdominal process has been established
  • mSOFA score ≥3 (in any one or combination of the 5 major components of SOFA score with one organ component having a score of at least 2: cardiovascular, respiratory, renal, coagulation, CNS), measured as close as possible to the first debridement, (but before first debridement is performed).
  • IV drug administration within 6 hours from the clinical diagnosis and the decision at the study site, to have an urgent surgical exploration and debridement (drug should not be administered until surgical confirmation is established).
  • If a woman is of childbearing potential, she must consistently use an acceptable method of contraception from baseline through Day 28. Acceptable birth control methods include oral contraceptive medication, an intrauterine device (IUD), an injectable contraceptive (such as Depo-Provera®), a birth control patch, a barrier method (such as condom or diaphragm with spermicide) or abstinence.
    • Non-childbearing potential is defined as current tubal ligation, hysterectomy, or ovariectomy or post-menopause (1 year without menses with an appropriate clinical profile at the appropriate age e.g. >45 years).
  • If a male patient’s sexual partner is of childbearing potential, the male patient must acknowledge that they will consistently use an acceptable method of contraception (defined above) from baseline through Day 28.
  • Signed and dated ICF as defined by the IRB and, if applicable, California Bill of Rights. By signing the ICF, the patient agrees to release any medical records pursuant to current Health Insurance Portability and Accountability Act (HIPAA) Guidelines. If patient is unable to comprehend or sign the ICF, patient’s legally acceptable representative may sign the ICF


Exclusion Criteria
  • Weight > 150 Kg / 330 pounds;
  • Patient who has been operated at least once for the current NSTI infection and had a curative deep tissue debridement (patients who underwent prior diagnostic minor surgery are allowed to enter into the study);
  • Patients with overt peripheral vascular disease in the involved area - associated with ischemic wounds/ulcers or gangrene, and /or other significant symptoms of inadequate vascular supply or where limb amputation is considered likely within 7 days due to the peripheral vascular disease;
  • Diabetic patients with peripheral vascular disease who present with below the ankle infection;
  • Recent deep vein thrombosis (DVT) event in the involved area in the last month
  • Patient with burn wounds;
  • Current condition of: (a) Inability to maintain a mean arterial pressure > 50 mmHg and/or systolic blood pressure > 70 mmHg for at least 1 hour prior to screening despite the presence of vasopressors and IV fluids or (b) a patient with respiratory failure such that an SaO2 of 80% cannot be achieved or (c) a patient with refractory coagulopathy (INR >5) or thrombocytopenia (platelet count less then 20,000) that does not partially correct with administration of appropriate factors or blood products,
  • Severe neurological impairment due to cerebrovascular accident or cardiac arrest
  • Recent cerebrovascular accident in the last 3 months.
  • Patients with cardiac arrest requiring cardiopulmonary resuscitation within the past 30 days;
  • Patient is not expected to survive throughout 28 days of study due to underlying medical condition, such as poorly controlled neoplasm (e.g. Stage III or IV cancer);
  • Patient or patient’s family are not committed to aggressive management of the patient’s condition, or the combination of necrotizing skin infection and underlying illness makes it unlikely that life support will be maintained;
  • Any concurrent medical condition, which in the opinion of the Investigator, may compromise the safety of the patient or the objectives of the study or the patient will not benefit from treatment such as:
    • CHF {NYHA class III-IV}
    • Severe COPD {GOLD stage III-IV. or chronic hypoxemia (PaO2 less then 55 mmHg) on room air, or chronic use of home ventilation, or unable to climb stairs or perform household duties due to chronic obstructive disease resulting in severe exercise restriction, or use of continuous home oxygen prior to hospital admission (sleep apnoea treated with continuous positive airway pressure or biphasic positive airway pressure oxygen during sleep is acceptable)}
    • Liver dysfunction {Childs-Pugh class C}
    • Immunosuppression (see Appendix F, Section ‎15.6 for list of excluded immunosuppressive medications)
    • Neutropenia less then 1,000 cells/mm3not due to the underlying infection
    • Receiving or about to receive chemotherapy or biologic anti-cancer treatment although hormonal manipulation therapies for breast and prostate malignancies are permitted
    • Hematological and lymphatic malignancies in the last 5 years
  • Known HIV infection with CD4 count less then 200 cells/mm3 or less then 14% of all lymphocytes;
  • Patients with known chronic kidney disease (documented pre-illness creatinine value(s) ≥2.0) or patients receiving renal replacement therapy for chronic kidney disease: either hemodialysis, peritoneal dialysis, hemofiltration such as Continuous Veno-Venous Hemofiltration (CVVH) or hemodiafiltration
  • Patients that are treated with continuous hemofiltration (e.g. Continuous Veno-Venous Hemofiltration) for acute kidney dysfunction, not due to NSTI, starting prior to study drug administration.
    Exception: Patients with acute kidney dysfunction due to NSTI may be enrolled in the event that the patient is off the treatment from time of study drug administration and up to at least one hour post study drug administration.
  • Pregnant or lactating women; Women of childbearing potential must have a negative subunit hCG pregnancy test immediately prior to study entry
  • Previous enrollment in a clinical trial involving investigational drug or a medical device within 30 days before provision of written informed consent for the study or within five half lives of the investigational drug, whichever is longer.
  • Previous enrollment in this protocol, ATB-202 or the Phase 2 trial of AB103, ATB-201.